On 12 November, HTL Biotechnology inaugurated HTL8, a new production unit at its Javené site in France dedicated to the manufacture of pharmaceutical-grade Polynucleotides.

Representing a €15 million investment, HTL8 is a new milestone in the Group’s industrial strategy. It is designed to meet growing global demand for biopolymers and to support new applications in regenerative medicine, ophthalmology and dermatology.

“[…] HTL8 is a perfect illustration of this: it anchors in France an industrial excellence capable of shining on a global scale, supporting our customers closely in their markets and contributing, through increasingly innovative pharmaceutical-grade biopolymers, to the healthcare solutions of tomorrow,” says François Fournier, CEO of HTL Biotechnology.

Discover how HTL8 strengthens our 45 years of expertise in polynucleotides, and what it means for our customers worldwide, in our press release.

Read the press release 

To see our most recent news,
follow us on LinkedIn

Go to our LinkedIn page